{"id":1666,"date":"2021-08-17T09:36:00","date_gmt":"2021-08-17T09:36:00","guid":{"rendered":"http:\/\/model1.caplinpoint.net\/?p=1666"},"modified":"2021-11-13T09:39:41","modified_gmt":"2021-11-13T09:39:41","slug":"caplin-steriles-receives-approval-from-brazils-anvisa","status":"publish","type":"post","link":"http:\/\/model1.caplinpoint.net\/index.php\/2021\/08\/17\/caplin-steriles-receives-approval-from-brazils-anvisa\/","title":{"rendered":"CAPLIN STERILES RECEIVES APPROVAL FROM BRAZIL\u2019S ANVISA"},"content":{"rendered":"\n<p><strong>Chennai, August 17, 2021:<\/strong> Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, has received approval from Brazil\u2019s National Health Surveillance Agency ANVISA (Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria) for its sterile injectable manufacturing site near Chennai, Tamilnadu. The approval grants access to the company to register and market its products in Brazil, the largest Pharmaceutical market in Latin America.<\/p>\n\n\n\n<p>Mr. C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited commented \u201cBrazil is an important target for Caplin Steriles\u2019 mid to long term expansion plans. As a first step, we will focus on extending our US approved products for Brazil.\u201d<\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"http:\/\/model1.caplinpoint.net\/wp-content\/uploads\/2021\/11\/17.08.2021-CAPLIN-STERILES-RECEIVES-APPROVAL-FROM-BRAZILS-ANVISA.pdf\" class=\"wp-block-file__button\" download=\"\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chennai, August 17, 2021: Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, has received approval from Brazil\u2019s National Health Surveillance Agency ANVISA (Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria) for its sterile injectable manufacturing site near Chennai, Tamilnadu. The approval grants access to the company to register and market its products in Brazil, the largest&#8230; <\/p>\n","protected":false},"author":1,"featured_media":1229,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"_links":{"self":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/1666"}],"collection":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/comments?post=1666"}],"version-history":[{"count":3,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/1666\/revisions"}],"predecessor-version":[{"id":1670,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/1666\/revisions\/1670"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media\/1229"}],"wp:attachment":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media?parent=1666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/categories?post=1666"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/tags?post=1666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}